

OPEN

Stable isotope metabolomics of pulmonary artery smooth muscle and endothelial cells in pulmonary hypertension and with TGF-beta treatment

Daniel Hernandez-Saavedra¹, Linda Sanders¹, Scott Freeman¹, Julie A. Reisz², Michael H. Lee¹, Claudia Mickael¹, Rahul Kumar^{1,3}, Biruk Kassa^{1,3}, Sue Gu¹, Angelo D' Alessandro², Kurt R. Stenmark⁴, Rubin M. Tuder¹ & Brian B. Graham^{1,3*}

Altered metabolism in pulmonary artery smooth muscle cells (PASMCs) and endothelial cells (PAECs) contributes to the pathology of pulmonary hypertension (PH), but changes in substrate uptake and how substrates are utilized have not been fully characterized. We hypothesized stable isotope metabolomics would identify increased glucose, glutamine and fatty acid uptake and utilization in human PASMCs and PAECs from PH versus control specimens, and that TGF- β treatment would phenocopy these metabolic changes. We used ¹³C-labeled glucose, glutamine or a long-chain fatty acid mixture added to cell culture media, and mass spectrometry-based metabolomics to detect and quantify ¹³C-labeled metabolites. We found PH PASMCs had increased glucose uptake and utilization by glycolysis and the pentose shunt, but no changes in glutamine or fatty acid uptake or utilization. Diseased PAECs had increased proximate glycolysis pathway intermediates, less pentose shunt flux, increased anaplerosis from glutamine, and decreased fatty acid β -oxidation. TGF- β treatment increased glycolysis in PASMCs, but did not recapitulate the PAEC disease phenotype. In TGF- β -treated PASMCs, glucose, glutamine and fatty acids all contributed carbons to the TCA cycle. In conclusion, PASMCs and PAECs collected from PH subjects have significant changes in metabolite uptake and utilization, partially recapitulated by TGF- β treatment.

Changes in cellular metabolism are increasingly recognized as a hallmark of pulmonary hypertension (PH) pathobiology¹⁻⁴. Shifts in the uptake of metabolic substrates and how they are utilized downstream enables the disease phenotype of vascular cells in PH, including increased proliferation, apoptosis resistance, hypertrophy and vasoconstriction³. One critical metabolic shift observed in PH is an increase in glycolysis, which is thought to occur in resident vascular wall cells including pulmonary artery smooth muscle cells (PASMCs), endothelial cells (PAECs) and fibroblasts⁵⁻⁷. Increased glucose uptake can be demonstrated *in vivo* by increased uptake of the glucose analog ¹⁸F-fluorodeoxyglucose in the lung parenchyma of PH subjects^{6,8}. The concept that glycolysis in PH is detrimental has led to investigation of the potential utility of dichloroacetate (DCA), which by blocking pyruvate dehydrogenase kinase causes increased glucose flux into the TCA cycle, and less glycolysis⁹. Glutamine uptake and metabolism by PAECs has also been shown to contribute to their disease phenotype¹⁰. However, comprehensive assessment of substrate uptake and how the substrates are utilized by pulmonary vascular cells in PH is lacking.

A potential driver of altered cellular metabolism is transforming growth factor β (TGF- β) signaling, which underlies many forms of heritable (through mutations in BMPR2 and other members of the TGF- β signaling superfamily) and idiopathic PAH, and PAH etiologies associated with other conditions such as autoimmune

¹Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. ²Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

³Department of Medicine, University of California San Francisco, San Francisco, CA, USA. ⁴Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. *email: brian.graham@ucsf.edu

Control Subjects			
PASMCs	PAECs	Age	Sex
X		25	M
X		55	F
X	X	24	M
X	X	50	F
X	X	36	F
	X	55	F
	X	49	M

Table 1. Age and sex of subjects for control PASMCs and PAECs.

Diseased Subjects							
Cells Used		Age	Sex	BMPR2 mut	Pre Txpl RHC		Medications
PASMCs	PAECs				mPAP (mmHg)	PVR ¹ (WU)	
X		57	F	N	82	27.3	S/A/E
X		16	M	N	63	20.5	T/-/E
X	X	40	M	N	73	16.8	S/A/T
X	X	27	F	c.76 + 5G > A ³	69	12.1	S/B/T
X	X	53	M	N	33	3.9	T/M/E
	X	16	F	N	95	N/A	S/-/T
	X	32	F	N	47	16.4	-/B/E

Table 2. Age, sex, BMPR2 mutations identified, pre-transplant right heart catheterization data, and PAH medication usage of subjects for diseased PASMCs and PAECs. All diseased subjects were clinically diagnosed with idiopathic pulmonary arterial hypertension (IPAH). ¹Calculated using Fick cardiac output. N/A: data not available. ²PDE5inh: PDE5 inhibitor; ERA: Endothelin Receptor Antagonist; Prost.: Prostacyclin Analog. Codes for each category (-: none used in that category): PDE5 inhibitor: S: sildenafil, T: tadalafil ERA: B: bosentan, A: ambrisentan, M: macitentan Prost.: E: epoprostenol, T: treprostinil (intravenous). ³Mutation judged likely pathogenic as it may disrupt mRNA splicing.

disease and schistosomiasis^{11–13}. TGF- β induces cellular phenotypes which require energy and metabolic substrates, including proliferation, migration, contraction, and synthesis of cytokines and the extracellular matrix.

Here, we hypothesized that PASMCs and PAECs obtained from subjects with idiopathic pulmonary arterial hypertension (IPAH) will have increased glycolysis, glutaminolysis, and fatty acid β -oxidation compared to cells from control subjects. We assessed the metabolism of primary cells derived from diseased and human donor lungs using stable isotope metabolomics, an approach that allows assessment of uptake and downstream utilization of labeled substrates. We found evidence of increased glycolysis and pentose shunt flux particularly in PASMCs. We also found evidence of increased glutamine metabolism in PAECs but not PASMCs. Diseased PAECs had evidence of less fatty acid metabolism. We were able to phenocopy aspects of the altered metabolic phenotype by treating the cells with TGF- β , most notably the glycolytic shift in PASMCs. Overall, our results indicate PASMCs and PAECs in PH have quite different changes in their metabolic phenotype, and future therapeutic interventions targeting metabolism will likely benefit from cell compartment specificity.

Results

We obtained primary PASMCs and PAECs from explanted IPAH and unsuccessful donor control lung specimens collected by the Pulmonary Hypertension Breakthrough Initiative (PHBI), a multi-center consortium that collects and distributes tissue specimens. We used N = 5 in each of the 4 categories (PASMCs and PAECs; diseased and control of each). The specimens had similar ages and sex distributions (Tables 1 and 2). Within these, we had N = 3 PASMCs and PAECs from the same diseased specimen, and N = 3 PASMCs and PAECs from the same control specimen. We added stable isotope-labeled metabolites—glucose, glutamine or a mixture of 4 long chain fatty acids—to the cell culture media, and following a 24 hour incubation, separated the supernatant from the cells and then performed metabolomics analysis on the samples.

Increased glucose uptake and utilization by glycolysis and the pentose shunt in diseased PASMCs.

We began by assessing the uptake and utilization of [1,2,3-¹³C₃]glucose in diseased versus control PASMCs. Glucose labeled at carbons 1-3 allows the comparative assessment of glucose metabolism through glycolysis versus the pentose shunt. When metabolized via glycolysis, ¹³C₃ lactate is generated; in contrast, the activity of pentose shunt enzyme 6-phosphogluconate dehydrogenase evolves ¹³C₁ as CO₂, and subsequently glyceraldehyde 3-phosphate and other downstream metabolites re-entering the glycolytic pathway will be labeled as ¹³C₂¹⁴. We observed a higher ¹³C-labeled pyruvate and lactate content within diseased PASMCs compared to control PASMCs, although no differences at the level of more proximate metabolites (Fig. 1a): data consistent with the




Figure 1. Analysis of ^{13}C -labeled metabolite content derived from $[1,2,3-^{13}\text{C}_3]$ glucose indicates increased glycolysis and pentose shunt flux in diseased PSMCs, and increased proximate glycolysis metabolites with decreased pentose shunt flux in diseased PAECs. **(a)** $^{13}\text{C}_3$ -Labeled glycolytic intermediates hexose phosphate (HP), fructose biphosphate (F2P), glyceraldehyde-3-phosphate (G3P), 1,3-bisphosphoglycerate (BPG), phosphoglycerate (PG), phosphoenolpyruvate (PEP), pyruvate (Pyr), and lactate (Lac) in the cell pellet or supernatant (Sup) of control or diseased PSMCs. **(b)** $^{13}\text{C}_2$ -Labeled glycolytic intermediates (derived from pentose shunt metabolism) glyceraldehyde-3-phosphate, 1,3-bisphosphoglycerate, phosphoglycerate, phosphoenolpyruvate, and lactate in control and diseased PSMCs cell pellet or supernatant; no $^{13}\text{C}_2$ -pyruvate was detected. **(c)** ^{13}C -labeled TCA cycle metabolites citrate (Cit), α -ketoglutarate (α Kg), succinate (Suc), fumarate (Fum) and malate (Mal); no labeled oxaloacetate was detected. **(d)** $^{13}\text{C}_3$ -Labeled glycolytic intermediates hexose phosphate, fructose biphosphate, glyceraldehyde-3-phosphate, 1,3-bisphosphoglycerate, phosphoglycerate, phosphoenolpyruvate, pyruvate, and lactate in the cell pellet or supernatant of control or

diseased PAECs; no $^{13}\text{C}_3$ -glyceraldehyde-3-phosphate or $^{13}\text{C}_3$ -phosphoglycerate were detected. (e) $^{13}\text{C}_2$ -Labeled 1,3-bisphosphoglycerate, phosphoenolpyruvate, and lactate in in control and diseased PAECs cell pellet or supernatant; no $^{13}\text{C}_2$ - glyceraldehyde-3-phosphate, phosphoglycerate, pyruvate or lactate in the pellet was detected. (f) ^{13}C -labeled citrate, α -ketoglutarate, succinate, fumarate and malate; no labeled oxaloacetate was detected. (N = 5 samples per group, from 5 different control and 5 different disease subjects; unpaired t-test; * $P < 0.05$, ** $P < 0.01$; mean \pm SEM plotted.) (g) Scatter plot of M + 3 lactate in the supernatant from PAECs and PSMCs obtained from the same individual (N = 3/group).




Figure 2. Analysis of ^{13}C -labeled metabolite content derived from [$^{13}\text{C}_5, ^{15}\text{N}_2$] glutamine indicates increased glutamine-derived anaplerosis in diseased PAECs but not PASM Cs. (a) ^{13}C and ^{15}N -labeled metabolites glutamine (Gln) and glutamate (Gln); citric acid cycle metabolites α -ketoglutarate (α Kg), succinate (Suc), fumarate (Fum), malate (Mal) and citrate (Cit; no $^{13}\text{C}_4$ -oxaloacetate was detected); and glutathione (GSH) in the cell pellet from control and diseased PASM Cs. (b) ^{13}C and ^{15}N -labeled metabolites glutamine and glutamate; citric acid cycle metabolites α -ketoglutarate, succinate, fumarate, malate and citrate (no $^{13}\text{C}_4$ -oxaloacetate was detected); and glutathione in the cell pellet from control and diseased PAECs. (N = 5 samples per group, from 5 different control and 5 different disease subjects; unpaired t-test; * $P < 0.05$; mean \pm SEM plotted).

observed shift to glycolysis in PASM Cs previously reported⁵. We observed an increase in $^{13}\text{C}_2$ -labeled lactate in the cell pellet similar to that observed with $^{13}\text{C}_3$ lactate (Fig. 1b), suggestive of increased pentose shunt flux in diseased PASM Cs. We also assessed for the ^{13}C enrichment of TCA cycle metabolites, but found no significant differences in the diseased cells (Fig. 1c). Overall, these results indicate IPA H PASM Cs have increased glucose metabolism through glycolysis and the pentose shunt, but not into the TCA cycle.

Diseased PAECs have increased proximate glycolysis metabolites, with less pentose shunt metabolism. In the PAECs, we observed a higher content of the proximate glycolysis metabolites, significantly for fructose biphosphate and a trend for hexose phosphate ($P = 0.051$; hexose phosphate is the combination of the isotopomers glucose phosphate and fructose phosphate), but no differences in more distal metabolites in the glycolytic pathway such as pyruvate or lactate (Fig. 1d). Also in contrast to the PASM Cs, we found a reduction in $^{13}\text{C}_2$ -lactate in the supernatant indicative of less pentose shunt flux (Fig. 1e). We found no significant changes in the incorporation of ^{13}C -labeled carbons into the TCA cycle in IPA H samples (Fig. 1f).

We looked for correlations in the glycolysis phenotype between PAECs and PASM Cs in the cells in each group derived from the same individual (N = 3/group) by assessing lactate in the supernatant, but did not observe any significant correlations (Fig. 1g). We compared cells derived from male versus female PA H subjects, and by pre-transplant PA H medication regimen, but found no differences (Supplementary Figs. 1 and 2). We also looked for correlations with the severity of disease, as measured by mean pulmonary artery pressure pre-transplant, but found no significant correlations (Supplementary Fig. 3). Finally, we assessed BMPR2 mRNA expression by RT-PCR in a subset of the samples (not including 1 sample with a BMPR2 mutation), and looked for correlations in the glycolysis phenotype with BMPR2 expression: we found suggestive inverse correlations in pyruvate content with BMPR2 expression in the cells, but otherwise observed no significant correlations (Supplementary Fig. 4).

PAECs but not PASM Cs have increased glutamine-derived anaplerosis. Glutamine is metabolized by cells as an alternative source of carbons to replenish the TCA cycle, a process termed anaplerosis. Using




Figure 3. Analysis of ^{13}C -labeled metabolite content derived from ^{13}C -labeled long chain fatty acids (LCFAs) indicates decreased fatty acid-derived anaplerosis in PAECs but not PASMCMs. **(a)** ^{13}C -Labeled LCFAs in the cell pellet from control and diseased PASMCMs. **(b)** $^{13}\text{C}_2$ -acyl-C2 and $^{13}\text{C}_2$ -labeled citric acid cycle metabolites citrate (Cit), succinate (Suc), fumarate (Fum) and malate (Mal); no $^{13}\text{C}_2$ - α -ketoglutarate or $^{13}\text{C}_2$ -oxaloacetate were detected. **(c)** ^{13}C -Labeled LCFAs in the cell pellet from control and diseased PAECs. **(d)** $^{13}\text{C}_2$ -Labeled citric acid cycle metabolites citrate, α -ketoglutarate, succinate, fumarate and malate; no $^{13}\text{C}_2$ -acyl-C2 or $^{13}\text{C}_2$ -oxaloacetate were detected. (N = 5 samples per group, from 5 different control and 5 different disease subjects; unpaired t-test; *** $P < 0.005$; mean \pm SEM plotted).

$^{13}\text{C}_5,^{15}\text{N}_2$]glutamine (all 5 carbons and both nitrogens labeled), we found no changes in the incorporation of glutamine-derived carbons into the TCA cycle in diseased PASMCMs compared to control cells (Fig. 2a). In PAECs, we observed the diseased cells had more ^{13}C -labeled succinate, consistent with increased glutamine-derived anaplerosis (Fig. 2b).

We also detected $^{13}\text{C}_5$ -citrate in the PAECs (Fig. 2b), indicating reductive carboxylation (or retrograde) metabolism in the TCA cycle, which has been previously described in endothelial cells¹⁵. There was no change in the degree of reductive carboxylation in IPAH cells. This species was not detected in the PASMCMs.

No Evidence of Significantly Altered Long Chain Fatty Acid Utilization by PASMCMs or PAECs.

We then assessed long chain fatty acid utilization by PASMCMs and PAECs. We employed a mixture of 4 uniformly stable isotope-labeled fatty acids, [$^{13}\text{C}_{16}$]palmitic acid (16:0), [$^{13}\text{C}_{16}$]palmitoleic acid (16:1), [$^{13}\text{C}_{18}$]oleic acid (18:1) and [$^{13}\text{C}_{18}$]linoleic acid (18:2). We employed a mixture to avoid bias in possible preferential uptake and utilization of specific fatty acids. We assessed the relative content of the four labeled fatty acid substrates remaining in the media of PASMCMs and PAECs after 24 hours, and found all four depleted to a comparable degree (data not shown).

In PASMCMs, we found no differences in the cellular content of the labeled fatty acids between IPAH and control cells (Fig. 3a). We also found no differences in the content of labeled ^{13}C -labeled two carbon fragments (the product of β -oxidation breakdown of labeled fatty acids), or $^{13}\text{C}_2$ -citrate resulting from incorporation of the two carbon fragments into the TCA cycle in the diseased cells (Fig. 3b).

In PAECs, we similarly found no significant changes in ^{13}C -labeled fatty acid incorporation into the cells (Fig. 3c). There was, however, a decrease in ^{13}C enrichment into the TCA cycle at the level of α -ketoglutarate in diseased compared to control cells (Fig. 3d), indicating a decrease in utilization of fatty-acid derived carbons in the TCA cycle.




Figure 4. Analysis of ^{13}C -labeled metabolite content derived from $[1,2,3-^{13}\text{C}_3]$ glucose indicates TGF- β increases glycolysis in PSMCs. (a,b) $^{13}\text{C}_3$ - and $^{13}\text{C}_2$ -Labeled lactate (M + 3 lactate is derived from glycolysis and M + 2 lactate is derived from pentose shunt metabolism) in the supernatant of (a) control or (b) diseased PSMCs, treated with or without TGF- β . (c,d) $^{13}\text{C}_3$ - and $^{13}\text{C}_2$ -Labeled lactate in the supernatant of (c) control or (d) diseased PAECs, treated with or without TGF- β . (N = 5 samples per group, from 5 different control and 5 different disease subjects; paired t-test; * $P < 0.05$).

TGF- β treatment also promotes increased glycolysis in PSMCs. Increased TGF- β signaling is a key component of many forms of human and experimental PH. We treated PSMCs and PAECs with TGF- β to see if this would phenocopy the disease phenotype in control cells, or augment the phenotype in diseased cells. We used 1 ng/mL of activated TGF- β 1, a physiologic dose that has been used extensively in both PSMC^{16,17} and PAEC^{18,19} studies.

Using the $[1,2,3-^{13}\text{C}_3]$ glucose substrate, we observed increased $^{13}\text{C}_3$ lactate in the supernatant of both control and diseased PSMCs treated with TGF- β , compared to respective untreated cells (Fig. 4a,b), indicating that TGF- β can phenocopy the glycolytic phenotype. We did not, however, find any significant changes in the production of $^{13}\text{C}_2$ lactate, indicating that TGF- β has less impact on pentose shunt flux. In PAECs, we found TGF- β treatment had no consistent effects on either $^{13}\text{C}_3$ or $^{13}\text{C}_2$ labeled glycolysis intermediates or lactate (Fig. 4c,d).

Using the $[^{13}\text{C}_5, ^{15}\text{N}_2]$ glutamine substrate, we found TGF- β treatment of control PSMCs decreased the incorporation of ^{13}C carbons into the TCA cycle, at the level of fumarate and malate (Fig. 5a)—in contrast to the absence of a phenotype between diseased and control PSMCs observed above. There was no significant impact of TGF- β on diseased PSMCs (Fig. 5b). TGF- β treatment did not appear to have a consistent impact on glutamine uptake or utilization by PAECs, although TGF- β did decrease $^{13}\text{C}_5$ -labeled α -ketoglutarate in the diseased cells (Fig. 5c,d).

Using the U- ^{13}C -labeled LCFA mixture, we observed control PSMCs treated with TGF- β had an increase in $^{13}\text{C}_2$ incorporation into citrate (Fig. 6a), and diseased PSMCs treated with TGF- β had an increase in the content of ^{13}C -labeled 2 carbon fragments in the cells (Fig. 6b)—indicative of increased fatty acid metabolism. In contrast, TGF- β treatment of control PAECs phenocopied the disease phenotype, with decreased $^{13}\text{C}_2$ - α -ketoglutarate (Fig. 6c,d).




Figure 5. Analysis of ^{13}C -labeled metabolites derived from $[^{13}\text{C}_5, ^{15}\text{N}_2]$ glutamine indicates decreased glutamine-derived anaplerosis in control PSMCs treated with TGF- β . **(a,b)** ^{13}C -Labeled citric acid cycle metabolites α -ketoglutarate (αKg), succinate (Suc), fumarate (Fum), malate (Mal) and citrate (Cit; no $^{13}\text{C}_4$ -oxaloacetate was detected) in the cell pellet from **(a)** control or **(b)** diseased PSMCs, treated with or without TGF- β . **(c,d)** ^{13}C -Labeled citric acid cycle metabolites α -ketoglutarate, succinate, fumarate, malate and citrate (no $^{13}\text{C}_4$ -oxaloacetate was detected) in the cell pellet from **(c)** control or **(d)** diseased PAECs, treated with or without TGF- β . (N = 5 samples per group, from 5 different control and 5 different disease subjects; paired t-test; * $P < 0.05$).

In TGF- β -treated PSMCs, glucose, glutamine and fatty acids are all carbon sources for the TCA cycle.

The TCA cycle is the hub for carbons metabolized by cells, both in terms of a destination for substrate catabolism and a source for anabolism. DCA is thought to function by increasing glucose flux into the TCA cycle, away from lactate⁵. We thus wondered if the metabolic shift seen in TGF- β -treated PSMCs would cause the majority of TCA cycle carbons to be derived from sources other than glucose. To assess this possibility, we sought to determine the relative contribution of carbons to TCA cycle intermediates in TGF- β treated PSMCs. To do so, we used cultured human PSMCs (Lonza) treated with inhibitors of glucose metabolism, glutamine metabolism, or fatty acid metabolism, and then assessed the change in uptake and incorporation of the substrates for each pathway. TGF- β treatment of the cultured PSMCs induced similar metabolic shifts compared to TGF- β treatment of the control donor PSMCs used above, including increased glycolysis and decreased glutaminolysis (data not shown).

We first confirmed that the metabolic inhibitors were effective. We observed that inhibiting hexokinase with 2-deoxyglucose significantly blocked the downstream metabolism of glucose (Fig. 7a); inhibiting glutaminase with CB-839 significantly blocked the downstream metabolism of glutamine (Fig. 7b); and inhibiting fatty acid transport into the mitochondria with the carnitine palmitoyltransferase 1 (CPT1) inhibitor oxfenicine significantly blocked fatty acid β -oxidation (Fig. 7c).




Figure 6. Analysis of ^{13}C -labeled metabolites derived from ^{13}C -labeled long chain fatty acids (LCFAs) indicates TGF- β increases the incorporation of fatty acid-derived carbons into the TCA cycle in PASMCS but decreases it in PAECs. **(a,b)** $^{13}\text{C}_2$ -acyl-C2 (a2:0) and $^{13}\text{C}_2$ -labeled citric acid cycle metabolites citrate (Cit), succinate (Suc), fumarate (Fum) and malate (Mal; no $^{13}\text{C}_2$ - α -ketoglutarate or $^{13}\text{C}_2$ -oxaloacetate were detected) in the cell pellet from **(a)** control or **(b)** diseased PASMCS, treated with or without TGF- β . **(c,d)** ^{13}C -Labeled citric acid cycle metabolites citrate, α -ketoglutarate (αKg), succinate, fumarate, and malate (no $^{13}\text{C}_2$ -acyl-C2 or $^{13}\text{C}_2$ -oxaloacetate was detected) in the cell pellet from **(c)** control or **(d)** diseased PAECs, treated with or without TGF- β . (N = 5 samples per group, from 5 different control and 5 different disease subjects; paired t-test; * $P < 0.05$).

We then quantified the relative incorporation of labeled substrates into $^{13}\text{C}_2$ -citrate with and without inhibition. We found that there were significant decreases in the incorporation of glucose blocked by 2-deoxyglucose and fatty acids blocked by oxfenicine, and a modest trend ($P = 0.11$) towards less incorporation of glutamine after CB-839 treatment (Fig. 7d). We then quantified the total (unlabeled) content of TCA cycle intermediates. We found significant decreases in the content of multiple TCA metabolites intermediates with all 3 treatments—2-deoxyglucose, CB-839, and oxfenicine—with the most significant decreases observed with 2-deoxyglucose treatment (Fig. 7e). These data indicate that in TGF- β -treated PASMCS—despite metabolic shifts including increased glycolysis, decreased glutamine-derived anaplerosis, and increased fatty acid β -oxidation—glucose, glutamine and fatty acids all contribute carbons to the TCA cycle, although potentially glucose more so than the others.

Discussion

Shifts in cellular metabolism have long been recognized as a hallmark of cancer pathobiology²⁰, and are increasingly recognized in PH as well. In both cancer and PH, one of the critical metabolic shifts is increased aerobic glycolysis (also known as the Warburg phenomenon), which supports a pro-proliferative, anti-apoptotic phenotype¹. In addition to increased glucose metabolism to lactate and not to TCA cycle intermediates, the Warburg phenomenon also includes aberrant mitochondrial oxygen sensing through epigenetic mechanisms, effectively




Figure 7. The TCA cycle of TGF- β -treated PSMCs derives carbons from glucose, glutamine and fatty acids. (a) Effect of the hexokinase inhibitor 2-deoxyglucose (2-DG) on $^{13}\text{C}_3$ -labeled glycolysis intermediates hexose phosphate (HP), fructose biphosphate (F2P), glyceraldehyde-3-phosphate (G3P), phosphoglycerate (PG), phosphoenolpyruvate (PEP), and lactate (Lac) derived from [1,2,3- ^{13}C]₃glucose in the cell pellet; no labeled $^{13}\text{C}_3$ -1,3-bisphosphoglycerate or $^{13}\text{C}_3$ -pyruvate were detected. (b) Effect of the transglutaminase inhibitor CB-839 on $^{13}\text{C}_5$, ^{15}N -glutamate (Glm) and $^{13}\text{C}_5$ - α -ketoglutarate (αKg) derived from [$^{13}\text{C}_5$, $^{15}\text{N}_2$]glutamine. (c) Effect of the carnitine palmitoyltransferase 1 inhibitor oxfenicine (Oxf) on intracellular fatty acid metabolites derived from ^{13}C -labeled fatty acids. (d) Effect of 2-deoxyglucose, CB-839 and oxfenicine on the contribution of $^{13}\text{C}_2$ to citrate deriving from ^{13}C -labeled glucose, glutamine and fatty acids, respectively. (e) Effect of 2-deoxyglucose, CB-839 and oxfenicine on the total content of the TCA metabolites citrate (Cit), α -ketoglutarate (αKg), succinate (Suc), fumarate (Fum), malate (Mal) and oxaloacetate (Oxa). (A-D: N = 3 samples per group, E: N = 3 samples per group, with 3 replicates, pooled; unpaired t-test between samples; * $P < 0.05$, ** $P < 0.01$, *** $P < 0.005$, **** $P < 0.001$; mean \pm SEM plotted).

resulting in “a state of pseudohypoxia” which contributes to PH pathogenesis²¹. Molecularly, hypoxia-inducible factor-1 α is a master regulator of glycolysis, and is increased in both PH and cancer^{22–24}.

Compared to glycolysis, pentose shunt metabolism has been less studied in PH. The enzyme which regulates glucose-6-phosphate entry into the pentose shunt, glucose-6-phosphate dehydrogenase, has been observed to be increased in hypoxic PSMCs²⁵. One function of the pentose pathway is the generation of cytosolic NADPH, which can be used to reduce oxidized glutathione (GSSG) and regenerate active site thiols in antioxidant enzymes in settings of oxidative stress which may be present in PH.

Altered TGF- β family signaling underlies many forms of pulmonary hypertension (PH), as evidenced by mutations in TGF- β pathway members underlying heritable PH; increased TGF- β signaling present in human and animal PH model lung tissue; and excessive activation of latent TGF- β ²⁶. Blockade of TGF- β signaling is protective in multiple forms of experimental PH^{13,27–29}, and clinical trials targeting TGF- β family ligands and receptors are currently ongoing. However, mechanisms by which aberrant TGF- β signaling results in the vascular pathology have not been fully elucidated. Knockdown of BMPR2 has shown to promote glycolysis³⁰; here in small numbers of samples we did not observe consistent trends between BMPR2 expression and glycolysis parameters. We did find evidence that TGF- β treatment can promote and augment a shift to glycolysis in PSMCs. These results are consistent with data that TGF- β can increase glucose utilization by fibroblasts³¹, although TGF- β did not phenocopy all aspects of the metabolic phenotype in IPAH cells.

We used stable isotope metabolic tracing *in vitro* in conjunction with mass spectrometry-based metabolomics to evaluate the uptake and utilization of three key metabolic substrates: glucose, glutamine and fatty acids. ¹³Carbon and ¹⁵N are non-radioactive and do not decay, and thus can be used for the tracing of labeled atoms into downstream metabolites³². Enzymes have a mild substrate preference for molecules containing lighter isotopes, which may induce bias in ¹³C-tracking studies, but in general these effects are thought to be very minor³³. Substrates other than glucose, glutamine and fatty acids may serve as alternative carbon and energy sources in mammalian cells, but these three compounds account for the majority of substrates. In the context of pathology, cells shift how carbon atoms flow through the cells: for example, in cancer cells the shift in glucose utilization to glycolysis from glucose oxidation is accompanied by increased glutaminolysis to fuel the TCA cycle³⁴. All three substrates have the potential to contribute carbon atoms to the TCA cycle, as we observed with PSMCs here.

Stable isotope metabolomics complements steady state metabolomics, which assesses the content of unlabeled metabolites in cells. Fessel *et al.* used steady-state metabolomics to study human PAECs transfected with mutant bone morphogenetic protein receptor 2 (BMPR2), a TGF- β receptor family member and a common driver of heritable human PH³⁵. The authors found an increase in proximate glycolytic pathway intermediates, which corresponds well with our data finding an increase in proximate ¹³C-labeled glycolytic pathway intermediates derived from ¹³C-labeled glucose. They also observed a decrease in fatty acid β -oxidation intermediates, which corresponds to the decrease in ¹³C-labeled α -ketoglutarate derived from ¹³C-fatty acid catabolism we observed. Finally, they also reported a decrease in glutamine-derived metabolites; here, our results diverge as we found evidence of increased labeled succinate derived from glutamine.

Endothelial cell proliferation has been reported to require all three of glycolysis, fatty acid β -oxidation and glutamine metabolism. In endothelial cells, glycolytic flux is mediated by upregulation of PFKFB3, and blockade of PFKFB3 can suppress angiogenesis³⁶. Fatty acid metabolism is also required for angiogenesis, but here the carbons are used for *de novo* nucleotide synthesis to support DNA replication³⁷. Blocking glutamine metabolism induces endothelial cell senescence³⁸, as observed by ourselves and others¹⁵, glutamine-derived α -ketoglutarate can undergo reductive carboxylation, likely to support the fatty acid and phospholipid anabolism required to maintain membrane homeostasis in these cells with a very high ratio of surface area to volume³⁹. The requirement for membrane synthesis in PAECs also supported by our observation that ¹³C labeled carbons may leave glycolysis at an intermediate step: glycerol is produced from glyceraldehyde 3-phosphate, and is also a critical component of phospholipids.

In PH, diseased PAECs have a decrease in oxygen consumption (corresponding to a decrease in mitochondrial respiration), and the density of mitochondria per cell is decreased in IPAH-derived PAECs compared to control PAECs⁶. Increased stiffness of the underlying matrix is sufficient to induce increased glycolysis and YAP/TAZ-dependent glutaminolysis in PAECs, a metabolic shift which supports proliferation of the cells¹⁰, and which we also found evidence for here in IPAH-derived cells. Endothelial-to-mesenchymal transition (EndoMT) of ECs, induced *in vitro* by a combination of TGF- β and IL-1 β , causes a decrease in fatty acid β -oxidation, while suppressing fatty acid β -oxidation (as we observed occurred in the PAECs treated with TGF- β) is sufficient to induce EndoMT⁴⁰.

To analyze fatty acid metabolism here we used a stable isotope-labeled mixture of palmitic acid, palmitoleic acid, oleic acid and lineolic acid to assess uptake and utilization in PSMCs and PAECs. This approach has the disadvantage of not allowing the discrete analysis of specific fatty acid substrates, which could be handled differently. However, the relevance of the substrates we analyzed is supported by the reported increase in circulating plasma concentrations of palmitic acid, oleic acid and lineolic acid by 12.0, 5.0 and 4.9-fold, respectively, in PAH versus control subjects⁴¹.

The pathologic phenotype of PH cells can be reversed, at least in part, by targeting the altered metabolism. Excessive proliferation and apoptosis resistance in PSMCs can be reversed by increasing glucose oxidation by treating the cells with DCA or blocking fatty acid oxidation such as with ranolazine, which increases glucose intake into the cells via the Randle cycle^{5,41,42}. Our studies broaden these data, with the observation that even in the context of increased glycolysis induced by TGF- β in PSMCs, glucose remains a major source of carbons for the TCA cycle.

The possibility of targeting the PH pathology by modulating metabolism has led to clinical trials using DCA as a pharmacologic treatment for PAH, which has shown promise particularly in individuals who lack genetic mutations in other pathways⁹. If pharmacologic TGF- β modulation has clinical benefit, such as by the ligand trap soterdacept, it is likely that a beneficial mechanism will be through modulating cellular metabolism. By targeting similar pathways, metabolic treatments may be found to have a synergistic effect with TGF- β pathway modulators.

An important limitation on making comparisons between PSMCs and PAECs in our study is the use of different cell culture media specific for smooth muscle and endothelial cells, which likely impacts the metabolic phenotype of the cells. For example, the smooth muscle cell media we used contains 2% fetal bovine serum (FBS) whereas the endothelial cell media contains 5% FBS: FBS contains hormones and other growth factors such as

insulin and cortisol that impact metabolism. Another limitation on comparing the relative uptake between different labeled metabolites is that the stable isotope-labeled metabolites were added to the media, adding to unlabeled metabolites already present. For example, the addition of [1,2,3-¹³C₃]glucose increased the total glucose concentration in the media, which may itself increase glucose uptake by cells⁴². We also have not, here, directly identified which metabolic pathways contribute to specific pathologic phenotypes in each cell type. Other limitations include the relatively small sample size, as primary cell lines obtained from cultured organs are a precious and scarce resource, and related to this we used cells at relatively high passage numbers because of the large number of experiments and numbers of cells required to generate high fidelity results.

In summary, we found evidence of a metabolic shift in diseased PSMCs, including increased glycolysis and pentose shunt flux. In PAECs, we found more modest changes, including an increase in several proximate intermediates in glycolysis, less pentose shunt flux, and increased glutamine-derived anaplerosis with less fatty acid fueling of the TCA cycle. These data suggest that therapeutic strategies addressing the altered cellular metabolism in PH may be most effective if they target specific cell compartments.

Methods

Cells and culture techniques. *Primary PSMCs and PAECs.* Primary PSMCs and PAECs were obtained from the cell studies core of the Pulmonary Hypertension Breakthrough Initiative (PHBI) Research Network (Philadelphia, PA). The PSMCs were cultured in Smooth Muscle Cell Medium (SMCM; ScienCell Research Laboratories, Carlsbad, CA; Cat#1101). The PAECs were cultured in Vasculife EC complete kit (Lifeline Cell Technology, Frederick, MD; Cat#LL-0005). Both the PSMC and PAEC media contain 5.5 mM glucose and 10 mM glutamine. Both PSMCs and PAECs were cultured at 37 °C with an atmosphere of 5% CO₂ (95% air) and 100% humidity. The cells were grown to no more than 90% confluence, and sub-cultured at a density of at least 5.0 × 10⁵ cells in 100 mm diameter dishes. Both primary cell types were used between passages 7 and 9. Viability was determined using trypan blue exclusion dye by light microscopy.

Cultured PSMCs. For the metabolic inhibitor experiments, we used cultured PSMCs from Lonza (Walkersville, MD; Cat#CC-2581). The cells were cultured as described above in SMCM.

Sample collection. PSMCs and PAECs from 5 controls (Failed Donors) and 5 diseased subjects (idiopathic pulmonary arterial hypertension; IPAH; see Table 1) were cultured in their respective culture media to 85–90% confluence, adding fresh media every 2–3 days (the rate of growth varied depending on cell type). When the cultures reached target confluence, the cells were treated under different conditions for 24 hours, at 37 °C with an atmosphere of 5% CO₂ (95% air) and 100% humidity. After 24 hours treatment, the cells were harvested; collecting 1 ml of supernatant media which was snap frozen in liquid nitrogen. The rest of the media was removed from the plate and the cells were washed twice with sterile PBS and trypsinized for 2–5 min at 37 °C. 3 ml of the respective cold media was added and the plate washed with 2 ml of cold ice PBS. The cells were pooled in 15 ml conical tubes and centrifuged 5 min at 1000 rpm at room temperature. The recovered pellet was then resuspended into 1 ml of ice cold PBS, and an aliquot counted via hemacytometer. The cell suspension was centrifuged 3 min at 1600 rpm at 4 °C and the final pellet snap frozen in liquid N₂. Media supernatants and cell pellets were stored at –70 °C until mass spectrometry analysis. Experiments using cultured PSMCs were performed in the same manner.

BMPR2 quantification. mRNA was isolated from PSMCs and PAECs, and RT-PCR used to quantify expression of BMPR2 and β-actin using the 2^{–ΔCt} method.

Treatments, including labeled metabolic substrates. Primary PSMCs and PAECs were treated with or without 1 ng/ml human recombinant human TGF-β1 (Invitrogen, Carlsbad, CA; Cat# 14-8348-62) at the same time as metabolic substrates were added to the respective culture media for the same duration of time, 24 hours. The metabolic substrates were 1 mg/ml of [1,2,3-¹³C₃]glucose (Sigma-Aldrich, St. Louis, MO, Cat#720127); 4 mM [¹³C₅,¹⁵N₂]glutamine (Cambridge Isotope Laboratories Inc., Tewksbury, MA; Cat# CNLM-1275-H); and 100 μM ¹³C_U-mixed fatty acids (Cambridge Isotope Laboratories Inc.; Cat# CLM-8455-1).

Cultured PSMCs were used for inhibition experiments using the same protocols as above, with the further addition of metabolic inhibitors, with 10 μM CB-839 (Sellechem, Houston TX; Cat# S7655); 1 mM 4-hydroxy-L-phenylglycine (oxfencine; Sigma-Aldrich; Cat# 56160); or 2 mg/ml 2-deoxy-D-glucose (Sigma-Aldrich; Cat# D8375).

Metabolomics assessment. Frozen cell pellets were extracted at 2 × 10⁶ cells/mL in ice cold lysis/extraction buffer (methanol:acetonitrile:water 5:3:2, v/v/v). Twenty μL of supernatant samples was extracted with 480 μL of extraction buffer. Samples were agitated at 4 °C for 30 min followed by centrifugation at 10,000 g for 10 min at 4 °C. Protein and lipid pellets were discarded, and extracts were injected (10 μL for cell samples; 20 μL for supernatant samples) into a UHPLC system (Vanquish, Thermo, San Jose, CA, USA) and run on a Kinetex C18 column (150 × 2.1 mm, 1.7 μm – Phenomenex, Torrance, CA, USA). Solvents were Optima H₂O (Phase A) and Optima acetonitrile (Phase B) supplemented with 0.1% formic acid for positive mode runs and 1 mM NH₄OAc for negative mode runs. Samples were analyzed using a 9 min gradient from 5–95% organic phase at 400 μL/min⁴³. The autosampler was held at 7 °C for all runs; the column compartment was held at 45 °C. The UHPLC system was coupled online with a Q Exactive mass spectrometer (Thermo, Bremen, Germany), scanning in Full MS mode (2 μscans) at 70,000 resolution in the 60–900 m/z range in negative and then positive ion mode (separate runs). Eluate was subjected to electrospray ionization (ESI) with 4 kV spray voltage. Nitrogen gas settings were 45 sheath gas and 15 auxiliary gas. Metabolite assignments and isotopologue distributions were determined

using Maven (Princeton, NJ, USA), following conversion of raw files to mzXML format through RawConverter. Chromatographic and MS technical stability were assessed by determining CVs for heavy and light isotopologues in a technical mixture of extract run every 10 injections.

Statistics. Relative quantitation was performed by exporting the values for integrated peak areas of light metabolites and their isotopologues into Excel (Microsoft, Redmond, CA, USA) for statistical analysis including t-test and ANOVA (significance threshold for p-values < 0.05). Data was plotted using GraphPad Prism (La Jolla, CA, USA). $P < 0.05$ was considered statistically significant.

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Received: 25 July 2019; Accepted: 16 December 2019;

Published online: 15 January 2020

References

- Culley, M. K. & Chan, S. Y. Mitochondrial metabolism in pulmonary hypertension: beyond mountains there are mountains. *J. Clin. Invest.* **128**, 3704–3715 (2018).
- Sutendra, G. & Michelakis, E. D. The metabolic basis of pulmonary arterial hypertension. *Cell Metab* **19**, 558–573 (2014).
- Plecitá-Hlavatá, L. *et al.* Metabolic Reprogramming and Redox Signaling in Pulmonary Hypertension. *Adv. Exp. Med. Biol.* **967**, 241–260 (2017).
- D'Alessandro, A. *et al.* Hallmarks of Pulmonary Hypertension: Mesenchymal and Inflammatory Cell Metabolic Reprogramming. *Antioxid. Redox Signal.* **28**, 230–250 (2018).
- Sutendra, G. *et al.* Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension. *Sci. Transl. Med.* **2**, 44ra58 (2010).
- Xu, W. *et al.* Alterations of cellular bioenergetics in pulmonary artery endothelial cells. *Proc. Natl. Acad. Sci. USA* **104**, 1342–1347 (2007).
- Zhang, H. *et al.* Metabolic and Proliferative State of Vascular Adventitial Fibroblasts in Pulmonary Hypertension Is Regulated Through a MicroRNA-124/PTBP1 (Polypyrimidine Tract Binding Protein 1)/Pyruvate Kinase Muscle Axis. *Circulation* **136**, 2468–2485 (2017).
- Zhao, L. *et al.* Heterogeneity in Lung 18FDG Uptake in Pulmonary Arterial Hypertension: Potential of Dynamic 18FDG Positron Emission Tomography With Kinetic Analysis as a Bridging Biomarker for Pulmonary Vascular Remodeling Targeted Treatments. *Circulation* **128**, 1214–1224 (2013).
- Michelakis, E. D. *et al.* Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. *Sci. Transl. Med.* **9**, (2017).
- Bertero, T. *et al.* Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension. *J. Clin. Invest.* **126**, 3313–3335 (2016).
- Kumar, R. *et al.* TGF- β activation by bone marrow-derived thrombospondin-1 causes Schistosoma- and hypoxia-induced pulmonary hypertension. *Nat. Commun.* **8**, 15494 (2017).
- Rol, N., Kurakula, K. B., Happé, C., Bogaard, H. J. & Goumans, M.-J. TGF- β and BMP2 Signaling in PAH: Two Black Sheep in One Family. *Int. J. Mol. Sci.* **19**, (2018).
- Long, L. *et al.* Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. *Nat. Med.* **21**, 777–785 (2015).
- Reisz, J. A. *et al.* Oxidative modifications of glyceraldehyde 3-phosphate dehydrogenase regulate metabolic reprogramming of stored red blood cells. *Blood* **128**, e32–42 (2016).
- Kim, B., Li, J., Jang, C. & Arany, Z. Glutamine fuels proliferation but not migration of endothelial cells. *EMBO J.* **36**, 2321–2333 (2017).
- Li, P. *et al.* ANP signaling inhibits TGF- β -induced Smad2 and Smad3 nuclear translocation and extracellular matrix expression in rat pulmonary arterial smooth muscle cells. *J. Appl. Physiol. Bethesda Md* **102**, 390–398 (2007).
- Thomas, M. *et al.* Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline. *Am. J. Pathol.* **174**, 380–389 (2009).
- Lu, Q. Transforming growth factor- β 1 protects against pulmonary artery endothelial cell apoptosis via ALK5. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **295**, L123–133 (2008).
- Lee, Y. H. *et al.* Transforming growth factor- β 1 effects on endothelial monolayer permeability involve focal adhesion kinase/Src. *Am. J. Respir. Cell Mol. Biol.* **37**, 485–493 (2007).
- Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. *Cell* **144**, 646–674 (2011).
- Archer, S. L. Pyruvate Kinase and Warburg Metabolism in Pulmonary Arterial Hypertension: Uncoupled Glycolysis and the Cancer-Like Phenotype of Pulmonary Arterial Hypertension. *Circulation* **136**, 2486–2490 (2017).
- Shimoda, L. A. & Semenza, G. L. HIF and the lung: role of hypoxia-inducible factors in pulmonary development and disease. *Am J Respir Crit Care Med* **183**, 152–156 (2011).
- Bonnet, S. *et al.* An abnormal mitochondrial-hypoxia inducible factor-1 α -Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. *Circulation* **113**, 2630–2641 (2006).
- Fijalkowska, I. *et al.* Hypoxia inducible-factor 1 α regulates the metabolic shift of pulmonary hypertensive endothelial cells. *Am. J. Pathol.* **176**, 1130–1138 (2010).
- Chettimada, S. *et al.* Hypoxia-induced glucose-6-phosphate dehydrogenase overexpression and -activation in pulmonary artery smooth muscle cells: implication in pulmonary hypertension. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **308**, L287–300 (2015).
- Humbert, M. *et al.* Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. *Eur. Respir. J.* **53**, (2019).
- Zaiman, A. L. *et al.* Role of the TGF- β /Alk5 signaling pathway in monocrotaline-induced pulmonary hypertension. *Am J Respir Crit Care Med* **177**, 896–905 (2008).
- Graham, B. B. *et al.* Transforming growth factor- β signaling promotes pulmonary hypertension caused by *Schistosoma mansoni*. *Circulation* **128**, 1354–1364 (2013).
- Nikolic, I. *et al.* Bone Morphogenetic Protein 9 Is a Mechanistic Biomarker of Portopulmonary Hypertension. *Am. J. Respir. Crit. Care Med.* **199**, 891–902 (2019).

30. Caruso, P. *et al.* Identification of MicroRNA-124 as a Major Regulator of Enhanced Endothelial Cell Glycolysis in Pulmonary Arterial Hypertension via PTBP1 (Polypyrimidine Tract Binding Protein) and Pyruvate Kinase M2. *Circulation* **136**, 2451–2467 (2017).
31. Nigdelioglu, R. *et al.* Transforming Growth Factor (TGF)- β Promotes de Novo Serine Synthesis for Collagen Production. *J. Biol. Chem.* **291**, 27239–27251 (2016).
32. Jang, C., Chen, L. & Rabinowitz, J. D. Metabolomics and Isotope Tracing. *Cell* **173**, 822–837 (2018).
33. Maggi, F. R., W. J. Mathematical treatment of isotopologue and isotopomer speciation and fractionation in biochemical kinetics. *Geochim. Cosmochim. Acta* **74**, 1823–1835 (2010).
34. Fan, J. *et al.* Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia. *Mol. Syst. Biol.* **9**, 712 (2013).
35. Fessel, J. P. *et al.* Metabolomic analysis of bone morphogenetic protein receptor type 2 mutations in human pulmonary endothelium reveals widespread metabolic reprogramming. *Pulm. Circ.* **2**, 201–213 (2012).
36. De Bock, K. *et al.* Role of PFKFB3-driven glycolysis in vessel sprouting. *Cell* **154**, 651–663 (2013).
37. Schoors, S. *et al.* Fatty acid carbon is essential for dNTP synthesis in endothelial cells. *Nature* **520**, 192–197 (2015).
38. Unterluggauer, H. *et al.* Premature senescence of human endothelial cells induced by inhibition of glutaminase. *Biogerontology* **9**, 247–259 (2008).
39. Ghesquière, B., Wong, B. W., Kuchnio, A. & Carmeliet, P. Metabolism of stromal and immune cells in health and disease. *Nature* **511**, 167–176 (2014).
40. Xiong, J. *et al.* A Metabolic Basis for Endothelial-to-Mesenchymal Transition. *Mol. Cell* **69**, 689–698.e7 (2018).
41. Hemnes, A. R. *et al.* Human PAH is characterized by a pattern of lipid-related insulin resistance. *JCI Insight* **4**, (2019).
42. Busik, J. V., Olson, L. K., Grant, M. B. & Henry, D. N. Glucose-induced activation of glucose uptake in cells from the inner and outer blood-retinal barrier. *Invest. Ophthalmol. Vis. Sci.* **43**, 2356–2363 (2002).
43. McCurdy, C. E. *et al.* Maternal obesity reduces oxidative capacity in fetal skeletal muscle of Japanese macaques. *JCI Insight* **1**, e86612 (2016).

Acknowledgements

Grant funding was provided by the American Heart Association Grants 17POST33670045 (RK), 19CDA34730030 (RK); the American Thoracic Society Foundation/Pulmonary Hypertension Association, and NIH grants P01HL014985 (KRS, RMT and BBG), R03HL133306 (BBG), and R01HL135872 (BBG)

Author contributions

Conception or design of the work: D.H.S., A.D.A., R.M.T., B.B.G. Data acquisition: D.H.S., L.S., S.F., J.A.R., M.H.L., C.M., R.K. and B.K. Data analysis: D.H.S., S.F., J.A.R., M.H.L., S.G. and B.B.G. Data interpretation: D.H.S., S.F., J.A.R., A.D.A., K.R.S., R.M.T. and B.B.G. Drafted the manuscript: D.H.S. and B.B.G. Substantial revisions of the manuscript: D.H.S., J.A.R., K.R.S. and B.B.G. All authors reviewed the manuscript and approved the final draft.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information is available for this paper at <https://doi.org/10.1038/s41598-019-57200-5>.

Correspondence and requests for materials should be addressed to B.B.G.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020